Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Creemers JHA, van der Doelen MJ, van Wilpe S, Hermsen R, Duiveman-de Boer T, Somford DM, Janssen MJR, Sedelaar JPM, Mehra N, Textor J, Westdorp H. Creemers JHA, et al. Among authors: hermsen r. Front Oncol. 2021 May 18;11:667658. doi: 10.3389/fonc.2021.667658. eCollection 2021. Front Oncol. 2021. PMID: 34084750 Free PMC article.
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Bosch D, van der Velden KJM, Oving IM, Wyndaele DNJ, Weijs LE, van Schelven WD, Oyen WJG, Te Beek ET, van de Luijtgaarden ACM, Somford DM, Nagarajah J, Hermsen R, Mehra N, Gerritsen WR, van der Doelen MJ, van Oort IM. Bosch D, et al. Among authors: hermsen r. J Nucl Med. 2024 Apr 1;65(4):541-547. doi: 10.2967/jnumed.123.266654. J Nucl Med. 2024. PMID: 38423781
Half-time bone scintigraphy in prostate and breast cancer patients.
Grootjans W, Serém SJ, Gomes MI, Heijmen L, Bulten BF, Mijnheere EP, Hermsen R, van den Broek WJ. Grootjans W, et al. Among authors: hermsen r. Q J Nucl Med Mol Imaging. 2018 Sep;62(3):303-312. doi: 10.23736/S1824-4785.16.02830-2. Epub 2016 Feb 16. Q J Nucl Med Mol Imaging. 2018. PMID: 26883516
Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.
de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ. de Geus-Oei LF, et al. Among authors: hermsen r. Ann Oncol. 2008 Feb;19(2):348-52. doi: 10.1093/annonc/mdm470. Epub 2007 Oct 24. Ann Oncol. 2008. PMID: 17962202 Free article.
124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
Kist JW, de Keizer B, van der Vlies M, Brouwers AH, Huysmans DA, van der Zant FM, Hermsen R, Stokkel MP, Hoekstra OS, Vogel WV; THYROPET Study Group; other members of the THYROPET Study group are John M.H. de Klerk. Kist JW, et al. Among authors: hermsen r. J Nucl Med. 2016 May;57(5):701-7. doi: 10.2967/jnumed.115.168138. Epub 2015 Nov 25. J Nucl Med. 2016. PMID: 26609180 Free article. Clinical Trial.
89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.
Verhoeff SR, van de Donk PP, Aarntzen EHJG, Oosting SF, Brouwers AH, Miedema IHC, Voortman J, Menke-van der Houven van Oordt WC, Boellaard R, Vriens D, Slingerland M, Hermsen R, Grunsven IVE, Heskamp S, van Herpen CML. Verhoeff SR, et al. Among authors: hermsen r. J Nucl Med. 2022 Oct;63(10):1523-1530. doi: 10.2967/jnumed.121.263470. Epub 2022 May 5. J Nucl Med. 2022. PMID: 35512998 Free PMC article.
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Küsters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA. Hermsen R, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3929-3937. doi: 10.1007/s00259-022-05827-4. Epub 2022 May 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 35543733 Clinical Trial.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
88 results